• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

Director Dealing

by alex | Aug 4, 2025 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Share Option Exercise

by chantal | Jul 16, 2025 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell initiates new arm (Cohort 4) in SCOPE Phase 2 study to evaluate intradermal administration and an accelerated dosing regimen for iSCIB1+

by chantal | Jun 25, 2025 | Immunobody, iSCIB1+, Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Director Dealing

by chantal | May 21, 2025 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Partnership with NHS Cancer Vaccine Launch Pad Enabling Fast-Tracked Access for Melanoma Patients

by chantal | Apr 14, 2025 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell to Present Clinical Data from the Ongoing Phase 2 SCOPE Trial of SCIB1 at 2025 AACR Annual Meeting

by chantal | Apr 1, 2025 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
« Older Entries
Next Entries »

Recent Posts

  • Result of General Meeting
  • Form F-4 (October 2026)
  • Preliminary Results for the year ended 30 April 2026
  • Atlantic crossing transforms outlook
  • Notice of General Meeting October 2026

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy